Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10065, USA.
Int J Gynecol Cancer. 2011 Apr;21(3):529-34. doi: 10.1097/IGC.0b013e31821091b5.
Serum CA125 is a potential biomarker for metastatic disease and recurrence in patients with uterine papillary serous carcinoma (UPSC).
All patients with UPSC who had preoperative CA125 measurement and surgical staging between 1998 and 2008 at the participating institutions were included in this analysis (N = 52). Data were extracted from patients' records. Fisher exact and χ² tests were used to assess the association of CA125 levels with clinical and pathological variables. The correlation between CA125 levels (high/low) and lymph node metastases (positive/negative) was evaluated using Spearman correlation coefficients. The association of CA125 elevation with recurrence-free survival was assessed using Cox proportional hazards regression modeling.
Preoperative CA125 elevation (>30 U/mL) was observed in 9 (17%) patients and was associated with advanced International Federation of Gynecologists and Obstetricians (FIGO) stage III/IV disease (P = 0.002), lymph node involvement (P = 0.007), and presence of omental metastases (P = 0.001). Disease recurrence and survival data were available for 51 of the 52 patients. During a mean follow-up time of 36 months, 15 (29%) patients experienced disease recurrence and 10 (19%) patients died. There was a moderate positive correlation between CA125 levels and lymph node metastases (r² = 0.39). On multivariate survival analysis, an elevated CA125 level compared to nonelevated CA-125 was not associated with disease recurrence (hazard ratio, 1.61; 95% confidence interval, 0.55-4.77).
Preoperative CA125 levels were significantly associated with metastatic disease in patients with UPSC. However, in this study of surgically staged UPSC patients, preoperative CA125 elevation was not an independent predictor of disease recurrence.
血清 CA125 是子宫乳头状浆液性癌（UPSC）患者转移疾病和复发的潜在生物标志物。
本分析纳入了 1998 年至 2008 年期间在参与机构接受术前 CA125 测量和手术分期的所有 UPSC 患者（N=52）。从患者的记录中提取数据。Fisher 确切检验和 χ²检验用于评估 CA125 水平与临床和病理变量的相关性。CA125 水平（高/低）与淋巴结转移（阳性/阴性）之间的相关性使用 Spearman 相关系数进行评估。使用 Cox 比例风险回归模型评估 CA125 升高与无复发生存率的相关性。
9 例（17%）患者术前 CA125 升高（>30 U/mL），与国际妇产科联合会（FIGO）晚期 III/IV 期疾病（P=0.002）、淋巴结受累（P=0.007）和大网膜转移（P=0.001）相关。52 例患者中有 51 例有疾病复发和生存数据。在平均 36 个月的随访期间，15 例（29%）患者发生疾病复发，10 例（19%）患者死亡。CA125 水平与淋巴结转移之间存在中度正相关（r²=0.39）。在多变量生存分析中，与 CA125 水平不升高相比，CA125 升高与疾病复发无关（危险比，1.61；95%置信区间，0.55-4.77）。
术前 CA125 水平与 UPSC 患者的转移性疾病显著相关。然而，在这项对手术分期 UPSC 患者的研究中，术前 CA125 升高不是疾病复发的独立预测因素。
